Zobrazeno 1 - 10
of 18
pro vyhledávání: '"M D Vincent"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
T W, Zhang, G B, Rodrigues, A V, Louie, D, Palma, A R, Dar, B, Dingle, W, Kocha, M, Sanatani, B, Yaremko, E, Yu, J, Younus, M D, Vincent
Publikováno v:
Current oncology (Toronto, Ont.). 25(1)
We designed a phase i study of concurrent chemoradiotherapy (ccrt) with docetaxel (D) and cisplatin (C), followed by consolidation dc, for unresectable stage iii non-small cell lung cancer (nsclc).Patients with histologically proven and unresectable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::152e90614f8247a38dec4cbd852e3fe4
https://pubmed.ncbi.nlm.nih.gov/29507480
https://pubmed.ncbi.nlm.nih.gov/29507480
Publikováno v:
Annals of Oncology
Background This study describes a repeated measures prediction index to identify patients at high risk of ≥ grade 2 hand-foot skin reaction (HFSR) before each week of sorafenib therapy. Methods Data from 451 patients who received a sorafenib (400 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d46492deb4a5ac6cfb594c6fe07c6e1
http://europepmc.org/articles/PMC3403729
http://europepmc.org/articles/PMC3403729
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 27(12)
Platinum drugs comprise one of the main classes of chemotherapy drugs that can induce remissions in various solid tumors. Although tumors often regress on treatment with cis-diamminedichloroplatinum II (cisplatin) or cis-diammine-1,1-cyclobutane dica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4ec9e3ae5e50aaaa48271f9cc77b7869
https://pubmed.ncbi.nlm.nih.gov/10570020
https://pubmed.ncbi.nlm.nih.gov/10570020
Publikováno v:
British journal of pharmacology. 127(8)
1. Thymidylate synthase (TS), the key enzyme in de novo synthesis of thymidine, is an important target for antitumour chemotherapy. It was hypothesized that antisense oligonucleotide down-regulation of TS mRNA would decrease TS levels and enhance the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dd9cc749a656e24f4ef886b9df4c1156
https://pubmed.ncbi.nlm.nih.gov/10482907
https://pubmed.ncbi.nlm.nih.gov/10482907
Publikováno v:
Journal of Clinical Oncology. 23:756-756
756 Background: Tesmilifene (DPPE), a novel chemopotentiating small molecule, conferred a substantial (50%+) increase in median survival in MA.19, a 305 patient randomized trial in ABC (doxorubicin...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17d2c7fbc7af668b3d901a772f430b77
https://doi.org/10.1200/jco.2005.23.16_suppl.756
https://doi.org/10.1200/jco.2005.23.16_suppl.756
Publikováno v:
European Journal of Cancer and Clinical Oncology. 23:1589-1599
Conventional staging in small cell lung cancer (SCLC) is only of limited prognostic value and is often based on elaborate investigations. We have carried out univariate and multivariate analysis of possible prognostic factors at presentation in 333 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80722d5a2df421ad5b9e2ff75df4319c
https://doi.org/10.1016/0277-5379(87)90436-6
https://doi.org/10.1016/0277-5379(87)90436-6
Publikováno v:
Journal of Clinical Oncology. 5:185-189
Fifty-two previously untreated patients with small-cell lung carcinoma (SCLC) were treated with a combination of carboplatin 300 mg/m2 intravenously (IV) on day 1 and etoposide 100 mg/m2 IV on days 1 through 3 every 28 days for four courses. Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36984b85a46b9299060b7a0b74a40ef9
https://doi.org/10.1200/jco.1987.5.2.185
https://doi.org/10.1200/jco.1987.5.2.185
Autor:
R. Skeet, Stanley W. Ashley, R. C. Coombes, S. Clarke, T. J. Powles, H. Adcock, M. D. Vincent, J. Gibb, H.L. Thomas
Publikováno v:
European Journal of Cancer and Clinical Oncology. 22:1059-1065
Factors influencing the extremes of survival in disseminated breast cancer were analysed. From a pool of 1066 patients with distant metastatic breast cancer, the 41 patients who had survived 5 yr or more from first distant recurrence were matched wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db580b964730dc180e907d8c4486fb85
https://doi.org/10.1016/0277-5379(86)90006-4
https://doi.org/10.1016/0277-5379(86)90006-4
Publikováno v:
Cancer chemotherapy and pharmacology. 21(1)
Response to second-line therapy in relapsing patients with small cell lung carcinoma (SCLC) is often claimed to be evidence in favour of non-cross resistance. Fifteen patients with SCLC who had relapsed off treatment after responding to initial first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b80e271c501015dc8192b86e42f3de7b
https://pubmed.ncbi.nlm.nih.gov/2830043
https://pubmed.ncbi.nlm.nih.gov/2830043